Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $224

Benzinga Newsdesk www.benzinga.com Positive 67.6%

Neg 0% Neu 0% Pos 67.6%

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $206 to $224.